Department of Medicine, Division of Rheumatology, National University School of Medicine, Bogota, Colombia.
Curr Rheumatol Rep. 2011 Dec;13(6):465-72. doi: 10.1007/s11926-011-0210-x.
Therapeutic management of the vasculitides is closely linked to modern rheumatologic advances, particularly as it relates to the discovery and first clinical use of glucocorticoids. These compounds were introduced in the late-1940s for the treatment of rheumatoid arthritis, but soon after, clinicians in Europe and the United States realized that they could have a significant positive impact in systemic vasculitides. However, once it was realized that glucocorticoid use was associated with a high degree of morbidity, the search for better immunosuppressive agents with similar efficacy but improved safety profiles was on. During the past several years, several agents have been utilized for the therapeutic management of systemic vasculitides, and the list keeps growing with the development of newer compounds that have retained efficacy but with a better safety profile.
血管炎的治疗管理与现代风湿病学的进展密切相关，特别是与糖皮质激素的发现和首次临床应用有关。这些化合物于 20 世纪 40 年代末被引入治疗类风湿关节炎，但不久之后，欧洲和美国的临床医生就意识到它们可以对系统性血管炎产生重大的积极影响。然而，一旦发现糖皮质激素的使用与高度发病率相关，人们就开始寻找具有相似疗效但安全性更好的更好的免疫抑制剂。在过去的几年中，已经有几种药物被用于系统性血管炎的治疗管理，而且随着具有更好安全性的新型化合物的开发，这个列表还在不断增加。
